Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | FGR | P09769 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26114064 | 0.99 | BTK (0.38) | BTKSYKAURKAFGRCYP2C9 | |
| Hydrochloric Acid SCHEMBL26114060 | 0.99 | BTK (0.38) | BTKSYKAURKAFGRCYP2C9 | |
| Hydrochloric Acid SCHEMBL30064702 | 0.99 | BTK (0.38) | BTKSYKAURKAFGRCYP2C9 | |
| SCHEMBL23816223 | 0.88 | BTK (0.36) | BTK | |
| Hydrochloric Acid SCHEMBL26115066 | 0.87 | BTK (0.36) | BTK | |
| Hydrochloric Acid SCHEMBL30063395 | 0.87 | BTK (0.36) | BTK | |
| Hydrochloric Acid SCHEMBL26115080 | 0.87 | BTK (0.36) | BTK | |
| SCHEMBL26114822 | 0.87 | BTK (0.38) | BTK | |
| SCHEMBL26114823 | 0.87 | BTK (0.38) | BTK | |
| SCHEMBL23816318 | 0.85 | BTK (0.39) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | BTK 1/4885SYK 4/4885AURKA 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.